Elimination efforts are challenged by the survival advantage of P. vivax in cooler temperatures, possible long latency with “overwintering” of parasites in the human host from one season to the next [4–6], and the need for deployment of diagnostic tests for glucose-6-phosphate dehydrogenase (G6PD) deficiency to provide radical cure safely with primaquine (PQ) [7, 8]. The gene discussed is G6PD; the disease is G6PD deficiency.